Capaccione, K.M.; Doubrovin, M.; Braumuller, B.; Leibowitz, D.; Bhatt, N.; Momen-Heravi, F.; Molotkov, A.; Kissner, M.; Goldner, K.; Soffing, M.;
et al. Evaluating the Combined Anticancer Response of Checkpoint Inhibitor Immunotherapy and FAP-Targeted Molecular Radiotherapy in Murine Models of Melanoma and Lung Cancer. Cancers 2022, 14, 4575.
https://doi.org/10.3390/cancers14194575
AMA Style
Capaccione KM, Doubrovin M, Braumuller B, Leibowitz D, Bhatt N, Momen-Heravi F, Molotkov A, Kissner M, Goldner K, Soffing M,
et al. Evaluating the Combined Anticancer Response of Checkpoint Inhibitor Immunotherapy and FAP-Targeted Molecular Radiotherapy in Murine Models of Melanoma and Lung Cancer. Cancers. 2022; 14(19):4575.
https://doi.org/10.3390/cancers14194575
Chicago/Turabian Style
Capaccione, Kathleen M., Mikhail Doubrovin, Brian Braumuller, Dev Leibowitz, Nikunj Bhatt, Fatemeh Momen-Heravi, Andrei Molotkov, Michael Kissner, Kimberly Goldner, Mark Soffing,
and et al. 2022. "Evaluating the Combined Anticancer Response of Checkpoint Inhibitor Immunotherapy and FAP-Targeted Molecular Radiotherapy in Murine Models of Melanoma and Lung Cancer" Cancers 14, no. 19: 4575.
https://doi.org/10.3390/cancers14194575
APA Style
Capaccione, K. M., Doubrovin, M., Braumuller, B., Leibowitz, D., Bhatt, N., Momen-Heravi, F., Molotkov, A., Kissner, M., Goldner, K., Soffing, M., Ali, A., & Mintz, A.
(2022). Evaluating the Combined Anticancer Response of Checkpoint Inhibitor Immunotherapy and FAP-Targeted Molecular Radiotherapy in Murine Models of Melanoma and Lung Cancer. Cancers, 14(19), 4575.
https://doi.org/10.3390/cancers14194575
